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1. Introduction 
Takotsubo cardiomyopathy is characterized by transient left ventricular systolic 
dysfunction and apical dyskinesis (ballooning) in the absence of significant obstructive 
coronary artery disease. Most patients with Takotsubo cardiomyopathy are females. An 
emotional stress is believed to be the main trigger of Takotsubo cardiomyopathy (Bybee 
& Prasad, 2008). Electrocardiographic features of Takotsubo cardiomyopathy might 
include: ST elevation, T wave inversion, and QT interval prolongation (Thakar et al., 
2011). 
QT interval prolongation might precede Torsades de Pointes - a potentially deadly 
polymorphic ventricular tachycardia. Female gender, left ventricular systolic dysfunction, 
recent conversion of atrial fibrillation to sinus rhythm, administering QT interval prolonging 
agents, hypokalemia, hypocalcemia, severe hypomagnesemia, and high-degree 
atrioventricular block, are all risk factors for acquired QT interval prolongation and 
Torsades de Pointes (Antzelevitch, 2007; Roden, 2004). 
The incidence of QT interval prolongation among patient with Takotsubo cardiomyopathy 
is higher than 50% (Abe et al., 2003; Cangella et al., 2007; Fang et al., 2008; Wittstein et al., 
2005), but the incidence Takotsubo cardiomyopathy-associated Torsades de Pointes is 
probably much lower. It is of great importance to study the clinical circumstances leading to 
Torsades de Pointes in patients with Takotsubo cardiomyopathy-associated QT interval 
prolongation since Torsades de Pointes might be fatal, while the prognosis of Takotsubo 
cardiomyopathy is usually good (Bybee & Prasad, 2008). 
Takotsubo cardiomyopathy-associated Torsades de Pointes has been reported in 2005 for 
the first time (Denney et al., 2005). We have reviewed this case report and additional 14 
reports (Akashi et al., 2003; Boulouffe et al., 2007; Finsterer et al., 2007; Furushima et al., 
2008; Ghosh et al., 2009; Hirose et al., 2008; Inoue et al., 2009; Kurisu et al., 2008; Mahida et 
al., 2009; Nault et al., 2007; Okada et al., 2007; Patel et al., 2007; Sasaki et al., 2006) 
concerning Takotsubo cardiomyopathy-associated Torsades de Pointes in 2009, and we 
have concluded that males with Takotsubo cardiomyopathy-associated QT interval 
prolongation are at risk for Takotsubo cardiomyopathy-associated Torsades de Pointes 
although most patients with Takotsubo cardiomyopathy are females. There has been a 
trend in the mean maximal QT interval being longer among patients with Takotsubo 
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cardiomyopathy-associated Torsades de Pointes relative to patients with Takotsubo 
cardiomyopathy-associated QT interval prolongation. Moreover, most patients with 
Takotsubo cardiomyopathy-associated Torsades de Pointes have had risk factors for 
Torsades de Pointes other than female gender and left ventricular systolic dysfunction 
(Samuelov-Kinori et al., 2009). Additional 12 patients with Takotsubo cardiomyopathy-
associated Torsades de Pointes have been reported since then (Ahn et al., 2011; Gotyo et 
al., 2009; Grilo et al., 2010; Kawano et al., 2010; Micallef et al., 2010; Pacha et al., 2010; 
Peters & Klein, 2011; Purvis et al., 2009; Rotondi et al., 2010; Wedekind et al., 2009; 
Yamada et al., 2011). We have currently examined whether our previous conclusions are 
true in face of these new publications. Moreover, we have studied if Torsades de Pointes 
has been possibly preventable in patients with Takotsubo cardiomyopathy-associated 
Torsades de Pointes. 
2. Material and methods 
2.1 Retrieval of reports 
We performed a literature search by using the following keywords: "Apical ballooning", 
"Arrhythmia", "Stress cardiomyopathy", "Sudden death", "Syncope", "Takotsubo", and 
"Torsades de Pointes". The references in each report were further reviewed for additional 
publications. Only full-length reports were reviewed. The study group included all patients 
with Takotsubo cardiomyopathy-associated Torsades de Pointes that had been reported 
until July 2011. The control group included patients with Takotsubo cardiomyopathy-
associated QT interval prolongation that had been reviewed previously (Samuelov-Kinori et 
al., 2009). 
2.2 Risk factors for Torsades de Pointes 
Each case report was analyzed for the presence of risk factors for Torsades de Pointes other 
than female gender and left ventricular systolic dysfunction: recent conversion of atrial 
fibrillation to sinus rhythm, administering QT interval prolonging agents, hypokalemia 
(<3.5 mmol/L), hypocalcemia (<8.5 mg/dL), severe hypomagnesaemia (<1 mg/dL), and 
high-degree atrioventricular block (Antzelevitch, 2007; Roden, 2004). Since genetic analysis 
was not available for all patients, suspicion of congenital long QT syndrome was also 
considered a risk factor for Torsades de Pointes, and was defined as QT interval 
prolongation in the baseline ECG recorded before Takotsubo cardiomyopathy appearance 
or following its resolution. QT interval prolongation was defined as QTc >430 msec for male 
patients and QTc >450 msec for female patients according to the Bazett's formula (Bazett, 
1920). We used the QTc that was mentioned in the text of each case report by the authors. In 
few cases we measured the QT interval length in lead II and calculated the QTc according to 
the ECG strip enclosed. 
2.3 Preventable Torsades de Pointes 
Each case report of Takotsubo cardiomyopathy-associated Torsades de Pointes was 
analyzed for the presence or the absence of treatment and prevention measures taken once 
QT interval prolongation had been noticed and prior to Torsades de Pointes appearance in 
face of the above-mentioned risk factors for Torsades de Pointes – regardless of whether 
Takotsubo cardiomyopathy diagnosis had already been made. 
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2.4 Statistical analysis 
Continuous variables were expressed as mean ± standard error. Student t-test was used to 
compare between mean values of continuous variables with parametric distributions. Mann-
Whitney test was used to compare between mean values of continuous variables with non-
parametric distributions. Fisher's exact test was used to compare between incidence and 
prevalence of categorical variables. Two-tailed p<0.05 was considered statistically significant. 
Version 17.0 of the SPSS statistical package was used for all statistical analyses (SPSS Inc., 
Chicago, IL, USA). 
3. Results 
Reports concerning 113 patients were reviewed. The study group included 27 patients with 
Takotsubo cardiomyopathy-associated Torsades de Pointes. The control group included 86 
patients with Takotsubo cardiomyopathy-associated QT interval prolongation. Mean age of 
all patients was 65.1±1.2 years. Most patients were females (n=102; 90.3%). All patients with 
Takotsubo cardiomyopathy-associated Torsades de Pointes survived, although one patient 
died of other complications more than two months following Torsades de Pointes (Hirose et 
al., 2008). 
Although most patients were females, the prevalence of male gender was significantly higher 
among patients with Takotsubo cardiomyopathy-associated Torsades de Pointes relative to 
patients with Takotsubo cardiomyopathy-associated QT interval prolongation (odds ratio 4.6; 
95%Cofidence Interval 1.3-16.7). Mean maximal QTc interval was significantly higher among 
patients with Takotsubo cardiomyopathy-associated Torsades de Pointes relative to patients 
with Takotsubo cardiomyopathy-associated QT interval prolongation even prior to Torsades 
de Pointes appearance. There were no statistical differences between patients with Takotsubo 
cardiomyopathy-associated Torsades de Pointes and patients with Takotsubo 
cardiomyopathy-associated QT interval prolongation in terms of mean age, mean lowest 
ejection fraction, and mean peak Troponin levels (table 1). 
 
 Takotsubo-
associated QT 
interval 
prolongation 
(n=86) 
Takotsubo-
associated 
Torsades de 
Pointes (n=27) 
p value 
Male gender 
n 
(%) 
5 
(5.8%) 
6 
(22.2%) 
0.021 
Age (years) 
n available 
Mean±SE 
86 
64.7±1.2 
27 
66.2±3.2 
0.680 
Maximal QTc interval 
(msec) 
n available 
Mean±SE 
58 
555.9±8.4 
25 
670.2±37.1 
0.006 
Maximal QTc interval prior to 
Torsades de Pointes (msec) 
n available 
Mean±SE 
58 
555.9±8.4 
16 
676.8±49.7 
0.029 
Lowest ejection fraction 
(%) 
n available 
Mean±SE 
50 
36.5±1.4 
11 
37.2±4.0 
0.850 
Peak Troponin levels 
(ng/mL) 
n available 
Mean±SE 
39 
5.6±2.5 
13 
1.7±0.8 
0.383 
Table 1. Clinical characteristics of reported patients 
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Overall, 17 (62.9%) patients with Takotsubo cardiomyopathy-associated Torsades de Pointes 
had one or more risk factors for Torsades de Pointes other than female gender and left 
ventricular systolic dysfunction, while only two (2.3%) patients with Takotsubo 
cardiomyopathy-associated QT interval prolongation had risk factors for Torsades de Pointes 
(odds ratio 71.4; 95%Confidence Interval 14.3-355.5; p<0.0001). Electrolyte depletion, i.e., 
hypokalemia and/or severe hypomagnesemia (n=7; 25.9%), and high-degree atrioventricular 
block (n=5; 18.5%), were the most prevalent risk factors for Torsades de Pointes and the last 
triggers for Torsades de Pointes. Four (14.8%) patients were also taking QT interval prolonging 
agents, although initiation of these agents was not the last trigger for Torsades de Pointes in 
any case (table 2). 
Among patients with Takotsubo cardiomyopathy-associated Torsades de Pointes, the 
arrhythmia was diagnosed prior to Takotsubo cardiomyopathy most of the times (n=19; 
70.4%), and in seven (25.9%) patients Torsades de Pointes was diagnosed upon admission 
to the emergency department. Nevertheless, Torsades de Pointes was possibly 
preventable in seven (25.9%) patients: In four patients with QT interval prolongation and 
apparent electrolyte depletion, hypokalemia and/or severe hypomagnesemia were 
corrected only following Torsades de Pointes appearance; in three patients with QT 
interval prolongation and high-degree atrioventricular block, pacemaker was implanted 
only following Torsades de Pointes appearance (table 2). In other patients, risk factors for 
Torsades de Pointes were diagnosed only following Torsades de Pointes appearance, or 
they were addressed too late. 
4. Discussion 
We have studied reports concerning patients with Takotsubo cardiomyopathy-associated 
QT interval prolongation and reports concerning patients with Takotsubo cardiomyopathy-
associated Torsades de Pointes in order to characterize the clinical circumstances leading to 
Torsades de Pointes in patients with Takotsubo cardiomyopathy. We have done this before 
in 2009 (Samuelov-Kinori et al., 2009), but reports concerning patients with Takotsubo 
cardiomyopathy-associated Torsades de Pointes have almost doubled since then, and it is 
time to examine if our previous conclusions are still true in face of these new publications. 
Moreover, we have studied if Torsades de Pointes has been possibly preventable in patients 
with Takotsubo cardiomyopathy-associated Torsades de Pointes. 
Consistent with our previous observation (Samuelov-Kinori et al., 2009), male patients with 
Takotsubo cardiomyopathy-associated QT interval prolongation are at higher risk for 
Torsades de Pointes compared with female patients with Takotsubo cardiomyopathy-
associated QT interval prolongation, although most patients with Takotsubo 
cardiomyopathy are females (Bybee & Prasad, 2008). This finding is coherent with a 
recognized paradox which is still unexplained: women have longer QT interval compared 
with men but lower incidence of sudden death (Larsen & Kadish, 1998). 
In our previous review there has been a trend in the mean maximal QT interval being longer 
among patients with Takotsubo cardiomyopathy-associated Torsades de Pointes relative to 
patients with Takotsubo cardiomyopathy-associated QT interval prolongation, although 
most of the times QT interval prolongation has been noticed only following Torsades de 
Pointes appearance (Samuelov-Kinori et al., 2009). In face of the new reports concerning 
patients with Takotsubo cardiomyopathy-associated QT interval prolongation, the trend has 
become statistically significant: mean maximal QTc interval is significantly higher among 
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First author Age Sex 
Diagnosed 
first 
Risk factors for QT interval prolongation 
and Torsades de Pointes other than 
female gender and left ventricular 
systolic dysfunction 
Was 
Torsades de 
Pointes 
preventable? 
Denney 32 M Torsades None No 
Kurisu 78 M Torsades Atrioventricular Block Possibly 
Kurisu 87 F Torsades Atrioventricular Block Possibly 
Nault 76 M Torsades HypoK Possibly 
Okada 77 M Takotsubo None No 
Akashi 67 F Torsades None No 
Boulouffe 68 F Takotsubo None No 
Finsterer 75 F Torsades Recent A.Fib conversion No 
Furushima 61 F Torsades QT interval prolongation at baseline ECG No 
Ghosh 59 F Takotsubo HypoK Possibly 
Patel 72 F Torsades* None No 
Sasaki 22 F Torsades* HypoK No 
Hirose 63 F Takotsubo HypoK + recent A.Fib conversion No 
Inoue 82 F Torsades* Atrioventricular Block No 
Mahida 55 F Torsades None No 
Micallef 58 F Takotsubo None No 
Pacha 64 F Takotsubo 
Recent A.Fib conversion + Amiodarone + 
HypoCa 
No 
Grilo 37 F Torsades 
Congenital long QT syndrome + 
Ketoconazole 
No 
Rotondi 57 F Takotsubo HypoK + HypoMg + HypoCa Possibly 
Wedekind 81 F Torsades* None No 
Gotyo 70 M Torsades None No 
Purvis 67 F Torsades HypoMg + Fluoxetine Possibly 
Kawano 80 M Torsades HypoK No 
Yamada 89 F Torsades* Atrioventricular Block No 
Yamada 81 F Torsades Clarythromycin No 
Peters 50 F Torsades* None No 
Ahn 78 F Takotsubo Atrioventricular Block Possibly 
Table 2. Clinical characteristics of patients with Takotsubo cardiomyopathy-associated 
Torsades de Pointes 
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patients with Takotsubo cardiomyopathy-associated Torsades de Pointes relative to patients 
with Takotsubo cardiomyopathy-associated QT interval prolongation even prior to 
Torsades de Pointes appearance. This finding is of great clinical significance beyond 
statistical significance: mean maximal QTc interval is remarkably high (676.8 msec) in 
patients with Takotsubo cardiomyopathy-associated Torsades de Pointes prior to Torsades 
de Pointes appearance - more than 120 msec higher relative to mean maximal QTc interval 
in patients with Takotsubo cardiomyopathy-associated QT interval prolongation without 
Torsades de Pointes appearance. This large difference in QT interval prolongation should 
urge physicians to start treatment and to take prevention measures as soon as possible prior 
to Torsades de Pointes appearance. 
As with our previous review (Samuelov-Kinori et al., 2009), most patients with Takotsubo 
cardiomyopathy-associated Torsades de Pointes have one or more risk factors for Torsades 
de Pointes other than female gender and left ventricular systolic dysfunction. Electrolyte 
depletion and high degree atrioventricular block are the most prevalent risk factors and last 
triggers for Torsades de Pointes. But this time we have also shown that Torsades de Pointes 
is possibly preventable in one quarter of the patients should electrolyte depletion and high 
degree atrioventricular block have been addressed earlier. 
4.1 Limitations 
Our study is based on a small number of published case reports. Accordingly, the above-
mentioned findings are suggestive rather than conclusive. We assume that there are more 
incidents of Torsades de Pointes in patients with Takotsubo cardiomyopathy that have not 
been published; for example, when physicians are reluctant to report their deceased 
patients. Indeed, in all the above-mentioned reports patients have survived Torsades de 
Pointes. Accordingly; we believe that our findings are more likely an underestimation of the 
true prevalence of the clinical circumstances that might lead to Torsades de Pointes in 
Takotsubo cardiomyopathy patients. 
4.2 Clinical implications 
This study defines four risk factors for Torsades de Pointes in patients with Takotsubo 
cardiomyopathy whom already have QT interval prolongation to begin with: male gander, 
marked QT interval prolongation, electrolyte depletion, and high degree atrioventricular 
block. Electrolyte depletion and high degree atrioventricular block are also last triggers for 
Torsades de Pointes in patients with Takotsubo cardiomyopathy. Accordingly, we believe 
electrolyte depletion and high degree atrioventricular block should be addressed as soon as 
possible in patients with Takotsubo cardiomyopathy in general, and in patients with 
marked QT interval prolongation in particular. 
5. Conclusion 
Men with Takotsubo cardiomyopathy-associated QT interval prolongation are at risk for 
Torsades de Pointes. Most patients with Takotsubo cardiomyopathy-associated Torsades de 
Pointes have risk factors for Torsades de Pointes other than female gender and left 
ventricular systolic dysfunction. Electrolyte depletion and high degree atrioventricular block 
are the most prevalent risk factors and last triggers for Torsades de Pointes. We wish to raise 
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the awareness of risk factors for Torsades de Pointes in patients with Takotsubo 
cardiomyopathy-associated QT interval prolongation. 
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